AGC Biologics announced on July 29, 2025, a development and manufacturing services agreement with Valneva SE to supply drug substance for its investigational tetravalent Shigella bioconjugate vaccine, S4V2. The drug substance will be produced at AGC Biologics' Heidelberg facility for use in Phase II studies.
This partnership builds on previous collaboration where AGC Biologics established GMP-compliant manufacturing for first-in-human studies. The new agreement focuses on ensuring supply for the ongoing Phase 2 infant study, initiated in April 2025, and the Phase 2b Human Challenge Study, launched in November 2024.
The supply of drug substance is a critical operational milestone, supporting the continued clinical advancement of S4V2, which is the world's most clinically advanced Shigella vaccine candidate. Shigellosis remains a significant global health threat, particularly for young children, with no approved vaccine currently available.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.